-
ATRA Reverses Cisplatin-Induced PARP Inhibitor Resistance
2026-09-05
The reference study shows that all-trans retinoic acid can reduce cisplatin-induced resistance to PARP inhibition in epithelial ovarian cancer models. Its sequential-treatment design links this effect to suppression of ALDH1A1, NAMPT, PARP1, and CHK1 expression together with reduced intracellular NAD+, supporting ATRA plus Niraparib as a mechanistically informed maintenance strategy.
-
ECL Western Blotting Substrate: Workflow Guide
2026-09-04
ECL Western Blotting Substrate (SKU K2187) provides a nonradioactive, luminol-based method for detecting HRP on immunoblots with chemiluminescent imaging. It is intended for HRP Western blot assays using X-ray film or CCD cameras, not for fluorescent or radioisotopic detection workflows.
-
Dabigatran Etexilate: Oral Thrombin Inhibition
2026-09-04
The reference review presents dabigatran etexilate as the first oral direct thrombin inhibitor marketed in the United States, emphasizing rapid, predictable anticoagulation without routine vitamin K antagonist monitoring. It connects the drug’s prodrug pharmacology and renal elimination with evidence in venous thromboembolism, nonvalvular atrial fibrillation, and acute VTE treatment, while highlighting bleeding risk and renal function as central limitations.
-
Machine Learning Designs LNPs for Microglia mRNA
2026-09-03
Rafiei, Shojaei, and Chau developed a machine learning workflow to connect lipid nanoparticle design with mRNA transfection and phenotype changes in activated microglia. The study identified HA-LNP2 as a lead formulation for IL10 mRNA and showed that its anti-inflammatory activity extended from a murine cell model to human iPSC-derived microglia.
-
Safe DNA Gel Stain for RNA Workflow Control
2026-09-03
Safe DNA Gel Stain supports safer DNA and RNA visualization when cloning, transcript quality control, or RNA-structure assays depend on recovering intact nucleic acids. Its blue-light compatibility helps reduce UV-associated damage, while defined in-gel and post-staining formats make it practical for routine molecular biology workflows.
-
Butylhydroxyanisole (BHA) in Cell Assays
2026-09-02
Learn how Butylhydroxyanisole (BHA), SKU C6525, can improve control of oxidation-related variability in cell viability, proliferation, and cytotoxicity workflows. This scenario-based guide covers solvent compatibility, stock preparation, controls, interpretation, and practical product-selection criteria.
-
Reporter mRNA as a Translational Control Surface
2026-09-02
A strategic guide to using Firefly Luciferase mRNA as more than a reporter: a formulation-aware control for delivery, translation, assay quality, and translational decision-making.
-
Lypressin Acetate: From Receptor to Assay
2026-09-01
Lypressin acetate connects vasopressin receptor biology with a rigorous, endpoint-driven assay strategy. This guide explains how to interpret its antidiuretic, vasopressor, and emerging antiviral evidence without confusing biological activity units with receptor potency.
-
Ivermectin: Assay Design for Parasitology Research
2026-09-01
Ivermectin is a broad-spectrum anti-parasitic compound whose value depends on rigorous control of mechanism, formulation, and phenotype. This article presents an assay-centered framework for parasitology research and uses GSDMC cancer biology as a carefully bounded lesson in translational experimental design.
-
NSP15 Inhibitor Screening Reveals Thymopentin and Oleuropein
2026-08-31
This 2021 study used structure-based virtual screening and molecular dynamics simulations to identify thymopentin and oleuropein as leading natural-product binders of the SARS-CoV-2 endoribonuclease NSP15. Its main contribution is a computational prioritization framework that links docking scores with complex stability, while also highlighting the need for biochemical and cellular validation before therapeutic interpretation.
-
Obeticholic Acid Workflows for Liver Fibrosis
2026-08-31
Obeticholic Acid provides a defined FXR-centered workflow for studying bile acid homeostasis, hepatocyte gene regulation, and liver disease phenotypes. This guide separates established product biology from exploratory extensions inspired by a 2025 fibrosis study, helping researchers build better controls, readouts, and troubleshooting plans.
-
mRNA Vaccine Memory and Safer LNP Design
2026-08-30
The reference study presents SAPC-LNPs, a sialic acid- and cleavable PEG-modified lipid nanoparticle designed to improve dendritic-cell delivery while limiting anti-LNP immune memory. In mice, this formulation reportedly produced stronger tumor-antigen memory, weaker LNP-directed memory, improved endosomal escape, and more durable antitumor protection than a commercial comparator.
-
LY2886721: Practical BACE1 Inhibition Workflows
2026-08-29
LY2886721 is a research-grade BACE inhibitor for connecting APP processing, amyloid beta reduction, and neuronal-function readouts. This workflow-oriented guide shows how to control solubility, define a partial-inhibition window, and pair biochemical endpoints with synaptic assays for more interpretable Alzheimer's disease treatment research.
-
Lithium, Rab11a, and Exosomal Wnt10a in Osteogenesis
2026-08-28
The reference study identifies a mechanistic route by which lithium enhances bone mesenchymal stem cell osteogenesis: MARK2-dependent trafficking of Rab11a–Rab11FIP1 complexes increases exosomal Wnt10a secretion, activating Wnt/β-catenin signaling. Its comparison of lithium-conditioned exosomes with control exosomes, including delivery through GelMA hydrogels, provides a framework for engineering extracellular vesicles for bone repair.
-
GSDMC Drives PDAC Stemness and Immune Evasion
2026-08-28
A 2024 Advanced Science study identifies Gasdermin C as a nuclear regulator of pancreatic ductal adenocarcinoma stemness, metastasis, and immune evasion, acting independently of classical pyroptosis. The work connects ADAM17-dependent GSDMC cleavage to promoter binding and CXCL9-associated immune remodeling, suggesting that blocking GSDMC processing or nuclear localization could improve responses to KRASG12D inhibition and PD-1 blockade.